Internal Medicine, Hematology & Oncology · Frederick, MD
NPI
1265619878
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2405 Whittier Drive, Suite 100
Frederick, MD, 21702
Phone (301) 682-2988
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.9M
216,904 services
Medicare patients, 2024
397
Average age 75
Drug cost, 2024
$4.4M
1,308 prescriptions
Company payments, 2025
$1,517
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mouhamad Bazzi was code J1453 (injection, fosaprepitant, 1 mg), 31,951 times for 30 patients. In total Mouhamad Bazzi billed 216,904 services in 108 codes, and Medicare paid $4.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 31,951 | 30 | $0.11 | $3,558 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,200 | 14 | $44.80 | $860K |
| J0897 Injection, denosumab, 1 mg | Office | 11,820 | 48 | $20.65 | $244K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 9,940 | 12 | $34.99 | $348K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 5,304 | 87 | $0.23 | $1,202 |
| 96375 Injection Administration | Office | 3,678 | 108 | $12.65 | $47K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,871 | 31 | $0.69 | $1,990 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,727 | 34 | $0.09 | $242 |
| J1750 Injection, iron dextran, 50 mg | Office | 2,238 | 79 | $13.47 | $30K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 2,093 | 127 | $0.51 | $1,067 |
| 99214 Office E&M - Established | Office | 1,922 | 332 | $103.08 | $198K |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 1,296 | 33 | $0.45 | $577 |
| J3490 Unclassified drugs | Office | 1,134 | 105 | $0.60 | $685 |
| J3480 Injection, potassium chloride, per 2 meq | Office | 1,100 | 26 | $0.08 | $92.67 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 980 | 16 | $0.26 | $252 |
By year: 2022 $4.6M for 191,852 services; 2023 $4.5M for 161,942 services; 2024 $4.9M for 216,904 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 333 | 70 | $7.76 | $2,584 |
Medicare prescription drug claims, 2024
In 2024, the drug Mouhamad Bazzi prescribed most often to Medicare patients was Eliquis (Apixaban), with 101 prescriptions and refills. In total Mouhamad Bazzi wrote 1,308 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 101 | 202 | 36 | $109K |
| Xarelto Rivaroxaban | 87 | 217 | 22 | $116K |
| Xtandi Enzalutamide | 72 | 74 | 14 | $1.0M |
| Potassium Chloride Generic | 62 | 110 | 27 | $3,545 |
| Levothyroxine Sodium Generic | 47 | 119 | 17 | $384 |
| Procrit Epoetin Alfa | 47 | 51 | 18 | $188K |
| Lupron Depot Leuprolide Acetate | 35 | 35 | Under 11 | $67K |
| Lanreotide Acetate Generic | 32 | 34 | Under 11 | $290K |
| Pantoprazole Sodium Generic | 31 | 68 | 16 | $346 |
| Prednisone Generic | 30 | 46 | 13 | $166 |
| Udenyca Pegfilgrastim-Cbqv | 27 | 27 | Under 11 | $150K |
| Ondansetron Hcl Generic | 27 | 27 | 23 | $216 |
| Prochlorperazine Maleate Generic | 25 | 28 | 23 | $471 |
| Nyvepria Pegfilgrastim-Apgf | 21 | 22 | Under 11 | $107K |
| Letrozole Generic | 20 | 60 | Under 11 | $423 |
Brand drugs: 668 claims; generic drugs: - claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mouhamad Bazzi $1,517 ($1,517 in general payments such as food, travel and fees) from 28 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $197.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 8 | $197 |
| Janssen Biotech, Inc. JNJ | 5 | $142 |
| GlaxoSmithKline, LLC. GSK | 5 | $135 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $124 |
| Pfizer Inc. PFE | 5 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $63.14 |
| Celgene Corporation BMY | 2 | $60.5 |
| Daiichi Sankyo Inc. 4568.T | 2 | $57.65 |
| Tempus AI, Inc TEM | 2 | $54.11 |
| Eisai Inc. 4523.T | 2 | $46.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.